Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
In Japan alone, around 4,000 individuals have a CIDP diagnosis.
Autoimmune Disorders
Vor Bio back from brink with autoimmune drug deal rising to $4bn
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
Harbour BioMed partners Otsuka on new T-cell therapy
Vertex halts development of diabetes cell therapy after trial failure
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Genentech eyes lupus market for Gazyva with positive Phase III data readout
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
